Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Gross Margin: 2009-2025

Historic Gross Margin for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to 69.91%.

  • Myriad Genetics' Gross Margin fell 32.00% to 69.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 70.36%, marking a year-over-year increase of 765.00%. This contributed to the annual value of 69.89% for FY2024, which is 125.00% up from last year.
  • As of Q3 2025, Myriad Genetics' Gross Margin stood at 69.91%, which was down 1.86% from 71.23% recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Gross Margin ranged from a high of 74.66% in Q2 2021 and a low of 33.24% during Q4 2022.
  • For the 3-year period, Myriad Genetics' Gross Margin averaged around 66.97%, with its median value being 69.55% (2024).
  • In the last 5 years, Myriad Genetics' Gross Margin crashed by 3,828bps in 2022 and then surged by 2,994bps in 2024.
  • Over the past 5 years, Myriad Genetics' Gross Margin (Quarterly) stood at 71.52% in 2021, then plummeted by 3,828bps to 33.24% in 2022, then surged by 847bps to 41.71% in 2023, then skyrocketed by 2,994bps to 71.65% in 2024, then slumped by 32bps to 69.91% in 2025.
  • Its Gross Margin stands at 69.91% for Q3 2025, versus 71.23% for Q2 2025 and 68.50% for Q1 2025.